RT Journal Article
T1 CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease.
A1 Pico, Sara
A1 Parras, Alberto
A1 Santos-Galindo, Maria
A1 Pose-Utrilla, Julia
A1 Castro, Margarita
A1 Fraga, Enrique
A1 Hernandez, Ivo H
A1 Elorza, Ainara
A1 Anta, Hector
A1 Wang, Nan
A1 Marti-Ssnchez, Laura
A1 Belloc, Eulalia
A1 Garcia-Esparcia, Paula
A1 Garrido, Juan J
A1 Ferrer, Isidro
A1 Macias-Garcia, Daniel
A1 Mir, Pablo
A1 Artuch, Rafael
A1 Perez, Belen
A1 Hernandez, Felix
A1 Navarro, Pilar
A1 Lopez-Sendon, Jose Luis
A1 Iglesias, Teresa
A1 Yang, X William
A1 Mendez, Raul
A1 Lucas, Jose J
K1 Humans
K1 Huntington Disease
K1 Transcription Factors
K1 mRNA Cleavage and Polyadenylation Factors
AB Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the basal ganglia for which disease-modifying treatments are not yet available. Although gene-silencing therapies are currently being tested, further molecular mechanisms must be explored to identify druggable targets for HD. Cytoplasmic polyadenylation element binding proteins 1 to 4 (CPEB1 to CPEB4) are RNA binding proteins that repress or activate translation of CPE-containing transcripts by shortening or elongating their poly(A) tail. Here, we found increased CPEB1 and decreased CPEB4 protein in the striatum of patients and mouse models with HD. This correlated with a reprogramming of polyadenylation in 17.3% of the transcriptome, markedly affecting neurodegeneration-associated genes including PSEN1, MAPT, SNCA, LRRK2, PINK1, DJ1, SOD1, TARDBP, FUS, and HTT and suggesting a new molecular mechanism in neurodegenerative disease etiology. We found decreased protein content of top deadenylated transcripts, including striatal atrophy–linked genes not previously related to HD, such as KTN1 and the easily druggable SLC19A3 (the ThTr2 thiamine transporter). Mutations in SLC19A3 cause biotin-thiamine–responsive basal ganglia disease (BTBGD), a striatal disorder that can be treated with a combination of biotin and thiamine. Similar to patients with BTBGD, patients with HD demonstrated decreased thiamine in the cerebrospinal fluid. Furthermore, patients and mice with HD showed decreased striatal concentrations of thiamine pyrophosphate (TPP), the metabolically active form of thiamine. High-dose biotin and thiamine treatment prevented TPP deficiency in HD mice and attenuated the radiological, neuropathological, and motor HD-like phenotypes, revealing an easily implementable therapy that might benefit patients with HD.
PB American Association for the Advancement of Science (AAAS)
YR 2021
FD 2021-09-29
LK https://hdl.handle.net/10668/27034
UL https://hdl.handle.net/10668/27034
LA en
NO Picó S, Parras A, Santos-Galindo M, Pose-Utrilla J, Castro M, Fraga E, et al. CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. Sci Transl Med. 2021 Sep 29;13(613):eabe7104.
DS RISalud
RD Jul 9, 2025